The clinical effect of salmeterol and fluticasone propionate combined with tiotropium in the treatment of chronic obstructive pulmonary disease
10.3760/cma.j.issn.1008-6706.2014.09.023
- VernacularTitle:沙美特罗／氟替卡松与噻托溴铵治疗慢性阻塞性肺疾病的临床效果
- Author:
Chuming YANG
- Publication Type:Journal Article
- Keywords:
salmeterol and fluticasone propionate;
tiotropium;
Pulmonary Disease,Chronic Obstructive
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(9):1328-1329
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effects of salmeterol and fluticasone propionate combined with tiotropium in treatment of chronic obstructive pulmonary disease (COPD).Methods 78 patients with COPD were randomly divided into two groups according to hospitalized order ,the control group(n=39)was given salmeterol and fluticasone propionate on the basis of the conventional treatment while the observation group ( n=39 ) was given tiotropium on the basis of the control group .The clinical efficacy and adverse events were compared between the two groups.Results After treatment,FVC,FEV1 and FEV1/FVC of the observation group were (1.90 ±0.19) L, (2.26 ±0.25)L and(68.41 ±5.65)%,which were significantly higher than those before treatment (t2 =9.92, 11.62,9.72;t1=9.70,8.76,9.41,all P<0.05)and of the control group(t=8.37,7.72,7.52,all P<0.05);the incidenceof adverse reactions had no statistically significant between the two groups (χ2 =2.207, P >0.05 ). Conclusion Salmeterol and fluticasone propionate combination of tiotropium in the treatment of COPD has significant effect,and it can effectively alleviate clinical symptoms and improve lung function ,so it is safe and reliable,which should be widely applied in clinical .
